Letter: Digoxin tablets: a possible problem with biological availability.
出版信息
Am Heart J. 1973 Nov;86(5):715. doi: 10.1016/0002-8703(73)90356-6.
PMID:4800276
Abstract
摘要
相似文献
1
Letter: Digoxin tablets: a possible problem with biological availability.
Am Heart J. 1973 Nov;86(5):715. doi: 10.1016/0002-8703(73)90356-6.
2
Editorial: Digoxin--the regulatory viewpoint.
Circulation. 1974 Mar;49(3):395-8. doi: 10.1161/01.cir.49.3.395.
3
Editorial: What the practicing physician should know about digoxin bioavailability and how will FDA action affect him?
Circulation. 1974 Mar;49(3):399-400. doi: 10.1161/01.cir.49.3.399.
4
Editorial: Bioavailability of drugs: focus on digoxin.社论：药物的生物利用度：聚焦地高辛。
Circulation. 1974 Mar;49(3):391-4. doi: 10.1161/01.cir.49.3.391.
5
Biologic availability of digoxin tablets.
JAMA. 1973 Apr 9;224(2):243.
6
Digoxin tablets.
Med Lett Drugs Ther. 1973 Nov 23;15(24):97-8.
7
Variation in biologic availability of digoxin from four preparations.四种制剂中地高辛生物利用度的差异。
N Engl J Med. 1971 Dec 9;285(24):1344-7. doi: 10.1056/NEJM197112092852403.
8
Dissimilarities of digoxin.
N Engl J Med. 1971 Dec 9;285(24):1376-7. doi: 10.1056/NEJM197112092852414.
9
Biological availability of digoxin from Lanoxin produced in the United Kingdom.英国生产的地高辛片剂（商品名：Lanoxin）中地高辛的生物利用度。
Br Med J. 1973 Nov 10;4(5888):323-6. doi: 10.1136/bmj.4.5888.323.
10
Letter: Discrepancy between solution and bioavailability of digoxin tablets.信函：地高辛片溶液与生物利用度之间的差异
Lancet. 1975 Mar 15;1(7907):629. doi: 10.1016/s0140-6736(75)91907-8.
Zotero 插件